We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...
CNBC reported that President Trump declared that sweeping US tariffs on imports from Mexico and Canada “will go forward” in a ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...
Wide-moat GSK’s fourth-quarter earnings were in line ... to oncology drugs Jemperli and Blenrep and immunology candidates depemokimab (ultra-long-acting IL-5 inhibitor for asthma and chronic ...
GSK’s global performance showed strength across key markets ... Five major product approvals are expected in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Key ...
This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...
including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments. For 2025, GSK expects turnover ...
plus over 4 billion pound sterling in combined peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results